Bjorkman DJ, Hammond EH, Lee RG, Clegg DO, Tolman KG: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988, 31: 1465–1472.
Article
CAS
PubMed
Google Scholar
Nohlgard C, Rubio CA, Kock Y, Hammar H: Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993, 28: 40–45.
Article
CAS
PubMed
Google Scholar
Jaskiewicz K, Voigt H, Blakolmer K: Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J Toxicol Clin Toxicol 1996, 34: 301–305.
Article
CAS
PubMed
Google Scholar
Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND: The canals of hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol 2004, 121: 324–329. 10.1309/5HR9-0TNC-4Q4J-RXWX
Article
CAS
PubMed
Google Scholar
Nyfors A: Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977, 85: 511–518.
CAS
Google Scholar
Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB: Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988, 85: 771–774.
Article
CAS
PubMed
Google Scholar
Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF: Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95: 1730–1734.
CAS
PubMed
Google Scholar
Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95: 3150–3156. 10.1111/j.1572-0241.2000.03287.x
Article
CAS
PubMed
Google Scholar
Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM: Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995, 133: 774–778.
Article
CAS
PubMed
Google Scholar
Boffa MJ, Chalmers RJ: Methotrexate for psoriasis. Clin Exp Dermatol 1996, 21: 399–408.
Article
CAS
PubMed
Google Scholar
Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO: Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004, 19: 391–399. 10.1046/j.1365-2036.2004.01819.x
Article
CAS
PubMed
Google Scholar
Reynolds FS, Lee WM: Hepatotoxicity after long-term methotrexate therapy. South Med J 1986, 79: 536–539.
Article
CAS
PubMed
Google Scholar
Robinson JK, Baughman RD, Auerbach R, Cimis RJ: Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980, 116: 413–415. 10.1001/archderm.116.4.413
Article
CAS
PubMed
Google Scholar
Nyfors A, Poulsen H: Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis. Am J Surg Pathol 1977, 1: 235–243.
Article
CAS
PubMed
Google Scholar
Langman G, Hall PM, Todd G: Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001, 16: 1395–1401. 10.1046/j.1440-1746.2001.02644.x
Article
CAS
PubMed
Google Scholar
Kremer JM, Koff R: A debate: should patients with rheumatoid arthritis on methotrexate undergo liver biopsies? Semin Arthritis Rheum 1992, 21: 376–386. 10.1016/0049-0172(92)90038-F
Article
CAS
PubMed
Google Scholar
Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ: Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10: 369–375.
Article
CAS
PubMed
Google Scholar
Ashton RE, Millward-Sadler GH, White JE: Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982, 79: 229–232. 10.1111/1523-1747.ep12500067
Article
CAS
PubMed
Google Scholar
Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC: Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994, 130: 204–210.
Article
CAS
PubMed
Google Scholar
Lanse SB, Arnold GL, Gowans JD, Kaplan MM: Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio. Dig Dis Sci 1985, 30: 104–109. 10.1007/BF01308193
Article
CAS
PubMed
Google Scholar
Kevat S, Ahern M, Hall P: Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp 1988, 3: 197–208.
CAS
PubMed
Google Scholar
Dolan OM, Burrows D, Irvine A, Walsh M: The value of a baseline liver biopsy prior to methotrexate treatment. Br J Dermatol 1994, 131: 891–894.
Article
CAS
PubMed
Google Scholar
British Society of Gastroenterology: Guidelines on the use of liver biopsy in clinical practice. 2004.
Google Scholar
Coulson IH, McKenzie J, Neild VS, Joseph AE, Marsden RA: A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy. Br J Dermatol 1987, 116: 491–495.
Article
CAS
PubMed
Google Scholar
Zachariae H, Aslam HM, Bjerring P, Sogaard H, Zachariae E, Heickendorff L: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991, 25: 50–53.
Article
CAS
PubMed
Google Scholar
Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY: Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996, 135: 538–544. 10.1046/j.1365-2133.1996.d01-1036.x
Article
CAS
PubMed
Google Scholar
Zachariae H, Heickendorff L, Sogaard H: The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001, 144: 100–103. 10.1046/j.1365-2133.2001.03959.x
Article
CAS
PubMed
Google Scholar
Mathew J, Burt AD: Cellular mechanisms of fibrogenesis in genetic haemochromatosis. In Cells of the hepatic sinusoid. Volume 4. Edited by: Knook DL and Wisse E. , The Kupffer Cell Foundation, Netherlands; 1993:274–276.
Google Scholar
Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, PC A: Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002, 16: 297–302.
Article
PubMed
Google Scholar
Hubscher SG: Iron overload, inflammation and fibrosis in genetic haemochromatosis. J Hepatol 2003, 38: 521–525. 10.1016/S0168-8278(03)00078-3
Article
CAS
PubMed
Google Scholar
Whiting-O'Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90: 711–716.
Article
PubMed
Google Scholar
Zachariae H, Sogaard H, Heickendorff L: Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up. Dermatology 1996, 192: 343–346.
Article
CAS
PubMed
Google Scholar